

## Tumours of the Central Nervous System Molecular Information Reporting Guide



www.stop Hersentumoren.nl Molecula		Molecular Informa	ation Repo	orting Gu	ıide	
Family/Las	st name			Date of birth	DD - MM - YYYY	
Given nan	ne(s)					
Patient ide	entifiers		Date of request		Accession/Laboratory number	
			DD - MM	- YYYY		
		<b>xt</b> are CORE. Elements in <b>grey text</b> are NO ect values indicates single select values		SCOPE	OF THIS DATASET SECTION	
	CLA	TO Tables 1-3 FOR CORE ELEMENTS REASSIFICATION (Elements from ALK/RO IMMUNOHISTOCHEMISTRY FINDING on the World Health Organization Classification	S1/MET/NTRK FA IGS are only requ	AMILY ALTERA	TIONS to OTHER tumours)	
ADEQUAC	Y OF SPE	CIMEN FOR MOLECULAR ASSESSMENT	ATRX ALTEI	RATIONS <sup>a</sup>		
		dequate for analysis	○ Indete ○ Absent			
<b>V</b>	cimen is in Crush	adequate for analysis (select all that apply)	$\sim$	t, <i>describe</i>		
	Autolysis		•			
	Cautery Necrosis		TESTING I	METHOD (select a	II that apply)	
	Decalcifica	ation		r sequencing		
		ell quantity	□ NGS	ased method		
	Fixation is	sues, specify	☐ IHC	iseu memou		
				determinate		
				tact nuclear expr ss of nuclear exp		
	Other, spe	ecify	_	specify		
•			•			
those b		blocks for ancillary studies, specify representing tumour and/or normal tissue	○ Indete ○ Absent	rminate	DUPLICATION <sup>a</sup>	
ALK/ROS	<i>1/MET/</i> N	TRK FAMILY ALTERATIONS	TESTING I	METHOD (select a	II that apply)	
○ Inde	eterminate		☐ ISH ☐ NGS			
○ Abse		ihe		Other, specify		
Present, describe			•			
		b	BRAF ALTER	RATIONS <sup>a</sup>		
TESTING METHOD <sup>b</sup> (select all that apply)  ☐ Immunohistochemistry (IHC)			BRAF vari			
☐ In situ hybridisation (ISH)			_	○ Indeterminate		
Next generation sequencing (NGS)			Absent BRAF p.V600E (c.1799T>A) variant present			
Other, specify			Other BRAF sequence variant present, specify			
Only care for some tymours, refer to Tables 1.3						
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.  b Repeat for each alteration.						

<b>BRAF</b> ALTERATIONS <sup>a</sup> continued	CDKN2A/B DELETION <sup>a</sup>		
VARIANTS ASSESSED (select all that apply)	○ Indeterminate		
p.V600E	Absent		
Any variant in exon 15	Homozygous deletion		
Other BRAF variant, specify	Hemizygous/heterozygous deletion		
•	TESTING METHOD (select all that apply)		
	☐ ISH		
BRAF variant continued	Array-based method		
TESTING METHOD (select all that apply)	□ NGS		
☐ Sanger sequencing	Other, specify		
NGS			
PCR-based method			
☐ IHC	CHROMOSOMAL ARM 1p/19q CODELETION <sup>a</sup>		
BRAF p.V600E expression	( ) Indeterminate		
Indeterminate	None detected		
Negative     Positive	1p/19q codeletion		
Other, specify	1p only deletion		
Variety, speemy	19q only deletion		
	Polysomy, <i>specify</i>		
BRAF rearrangement/duplication	<b>→</b>		
<ul><li>☐ Indeterminate</li><li>☐ Absent</li></ul>	TESTING METHOD (select all that apply)		
Present, describe	☐ ISH		
Treserie, describe	Array-based method (including methylation arrays <sup>c</sup> )		
	☐ PCR/Loss of heterozygosity assay		
VARIANTS ASSESSED (select all that apply)	NGS		
☐ KIAA1549::BRAF fusion	Other, specify		
☐ BRAF::RAF1 fusion			
Other, <i>specify</i>			
	CHROMOSOME 7 GAIN (COMBINED WITH CHROMOSOME		
	10 LOSS) <sup>a</sup>		
TESTING METHOD (select all that apply)	☐ Indeterminate		
☐ ISH	Absent		
☐ RT-PCR	Present, describe		
Array-based method	•		
RNA-sequencing			
Other, specify	TESTING METHOD (select all that apply)		
	☐ ISH		
	Array-based method		
C19MC ALTERATIONS <sup>a</sup>	□ NGS		
○ Indeterminate	Other, specify		
Absent			
Present with low level gain			
Present, describe including copy number	CIC ALTERATIONS <sup>a</sup>		
•	( ) Indeterminate		
	Absent		
TESTING METHOD (select all that apply)	Present, describe		
☐ ISH	¥		
Array-based method			
□ NGS	TESTING METHOD (select all that apply)		
Other, specify	_ IHC		
*	☐ ISH		
	□ NGS		
LIN28A expression (IHC) <sup>a</sup>	Other, specify		
○ Indeterminate	<b>▼</b>		
○ Negative			
Opositive	<sup>c</sup> Methylation array-based methods may provide strong but circumstantial		
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.	evidence.		

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org)

Version 2.0 Published September 2024

ISBN: 978-1-922324-44-3

Page 2 of 7

DICER1 ALTERATIONS <sup>a</sup>	FGFR FAMILY ALTERATIONS <sup>a</sup>		
○ Indeterminate	○ Indeterminate		
Absent	Absent		
Present, <i>describe</i>	Present, describe		
•	<b>V</b>		
TESTING METHOD (select all that apply)			
☐ IHC	TESTING METHOD <sup>b</sup> (select all that apply)		
☐ ISH	☐ IHC		
□ 1311	☐ ISH		
Other, specify	□ NGS		
Ottlei, specify	Other, specify		
EGFR ALTERATIONS <sup>a</sup>			
EGFR amplification	FOXR2 ALTERATIONS <sup>a</sup>		
○ Indeterminate	○ Indeterminate		
Absent	Absent		
Absent with low level gain	Present, describe		
Present, describe including copy number	<b>V</b>		
	TESTING METHOD (select all that apply)		
TESTING METHOD (select all that apply)	☐ IHC		
☐ ISH			
☐ Array-based method			
□ NGS	☐ NGS		
Other, specify	Other, specify		
☐ Indeterminate ☐ Absent ☐ Present, describe ☐ TESTING METHOD (select all that apply) ☐ NGS ☐ PCR-based method ☐ IHC ☐ Other, specify	Histone H3 gene family variants  Indeterminate  Negative  Positive for K27M  Positive for G34R or G34V  Positive, for other H3 variants, specify  TESTING METHOD (select all that apply)  Sanger sequencing  NGS		
EZUID EVEDECCION (TUC) <sup>a</sup>	☐ PCR-based method		
EZHIP EXPRESSION (IHC) <sup>a</sup>	THC		
○ Indeterminate	Histone H3 K27M expression		
Negative	○ Indeterminate		
Opositive	Negative		
FET ALTERATIONS <sup>a</sup>	Positive		
○ Indeterminate	Histone H3 G34R expression		
Absent	Indeterminate		
Present, describe	Negative		
<b>▼</b>	Positive		
TESTING METHOD (select all that apply)	Histone H3 K27me3 expression		
☐ IHC	Indeterminate		
☐ ISH	Intact expression		
□ NGS	C Loss of expression		
Other, specify	Other, specify		
<b>V</b>			
a	b		
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.	b Repeat for each alteration.		

	MN1 ALTERATIONS <sup>a</sup>
○ Indeterminate	( ) Indeterminate
Absent	Absent
	Present, describe
Present, describe	Present, describe
TECTING METHOD (called all that each)	
TESTING METHOD (select all that apply)	TESTING METHOD (select all that apply)
Sanger sequencing	☐ IHC
□NGS	☐ ISH
PCR-based method	□NGS
☐ IHC	Other, specify
IDH1 R132H expression	
( ) Indeterminate	
Negative	
OPositive	
$\odot$	MYB, MYBL1 ALTERATIONS <sup>a</sup>
Other, specify	
	<u> </u>
	Absent
	Present, <i>describe</i>
PK PATHWAY ALTERATIONS 📗	•
○ Indeterminate	
	h
Absent	TESTING METHOD <sup>b</sup> (select all that apply)
NF1 loss, describe	☐ IHC
	☐ ISH
	_
For BRAF-KIAA1549 alterations refer to <b>BRAF</b>	☐ NGS
ALTERATIONS	Other, specify
	•
For FGRFR alterations refer to FGFR FAMILY ALTERATIONS	
Positive for other MAPK alteration, describe	
<b>Y</b>	MYC GENE FAMILY AMPLIFICATION (MYC and/or MYC)
TESTING METHOD <sup>b</sup> (select all that apply)	○ Indeterminate
	Absent
☐ IHC	Absent with low level gain
☐ ISH	
□ NGS	Present, describe including copy number
Other, <i>specify</i>	
	1
	TESTING METHOD <sup>b</sup> (select all that apply)
	TESTING METHOD (select all that apply)
	☐ ISH
THYLOME PROFILING <sup>a</sup>	Array-based method
ssifier (e.g., Heidelberg   Version   Methylation class   Scor	
(eigi, neidelberg   Faraion   Pretriyiation class   Stor	-
	Other angif:
	Other, specify
	PDGFRA ALTERATIONS <sup>a</sup>
	PDGFRA ALTERATIONS <sup>a</sup>
	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent
in Tumour Classifier) (e.g., 12.5)	PDGFRA ALTERATIONS <sup>a</sup>
in Tumour Classifier) (e.g., 12.5)  MGMT promoter status	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent
in Tumour Classifier) (e.g., 12.5)	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent
(e.g., 12.5)  ### ### ### ### ### ### ### ### ### #	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number
Indeterminate Unmethylated	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)
### Immour Classifier) (e.g., 12.5)  ###################################	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)  IHC
### Immour Classifier) (e.g., 12.5)  ###################################	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)
### Immour Classifier) (e.g., 12.5)  ###################################	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)  IHC
MGMT promoter status  Indeterminate  Unmethylated	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply) IHC ISH NGS
MGMT promoter status  Indeterminate Unmethylated Methylated	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)  IHC ISH
MGMT promoter status  Indeterminate Unmethylated Methylated	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply)  IHC ISH NGS
MGMT promoter status Indeterminate Unmethylated Methylated Most informative copy number variations, specify	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply) IHC ISH NGS
MGMT promoter status  Indeterminate Unmethylated Methylated	PDGFRA ALTERATIONS <sup>a</sup> Indeterminate Absent Present, describe including copy number  TESTING METHOD (select all that apply) IHC ISH NGS

PITUITARY HORMONES AND TRANSCRIPTION FACTORS IMMUNOHISTOCHEMISTRY <sup>a</sup>	SHH PATHWAY ALTERATIONS <sup>a</sup> Indeterminate
Tumour cells are reactive for (select all that apply)	Absent
○ Indeterminate	Present, describe
Prolactin	Present, describe
Human growth hormone	
☐ β-TSH	
 ☐ β-FSH	TESTING METHOD <sup>b</sup> (select all that apply)
 ☐ β-LH	☐ IHC
☐ Alpha subunit	☐ISH
ACTH	□NGS
☐ PIT1	Other, specify
☐ TPIT	<b>V</b>
☐ SF1	
Other, specify	
<b>V</b>	SMARC FAMILY ALTERATIONS <sup>a</sup>
	SMARCA4/BRG1 alteration
PRC2 ALTERATION <sup>a</sup>	○ Indeterminate
	Absent
<ul><li>○ Indeterminate</li><li>○ Absent</li></ul>	Present, describe sequence variant(s)
Present, describe	
Present, describe	
	TESTING METHOD (select all that apply)
TESTING METHOD (select all that apply)	☐ Sanger sequencing
	□ NGS
☐ ISH	PCR-based method
□ NGS	Other, specify
Other, specify	
<b>V</b>	
	BRG1 loss of expression (IHC)
a	(Indeterminate
PRKAR1A ALTERATION <sup>a</sup>	Intact nuclear expression
○ Indeterminate	Loss of nuclear expression
Absent	Coss of musical expression
Present, describe	SMARCB1/INI1/SNF5 alteration
	○ Indeterminate
	Absent
TESTING METHOD (select all that apply)	Present, describe sequence variant(s)
☐ IHC	<b>T</b>
☐ ISH	
☐ NGS ☐ Other, <i>specify</i>	TESTING METHOD (select all that apply)
Other, specify	☐ Sanger sequencing
	□ NGS
	☐ PCR-based method
PRKCA ALTERATION <sup>a</sup>	Other, specify
Indeterminate	<b>V</b>
Absent	
Present, describe	TNT1 (DAE47) loss of our receive (TUO)
¥	INI1 (BAF47) loss of expression (IHC)
	○ Indeterminate
TESTING METHOD (select all that apply)	Intact nuclear expression
☐ IHC	Loss of nuclear expression
☐ ISH	b Repeat for each alteration.
□ NGS	
Other, <i>specify</i>	
<b>V</b>	
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.	

STAT6 ALTERATIONS <sup>a</sup> STAT6 expression (IHC) Indeterminate Absence of nuclear expression Positive nuclear expression  STAT6 rearrangement Indeterminate Absent	TTF1 EXPRESSION (IHC) <sup>a</sup> Indeterminate  Negative  Positive  WNT PATHWAY ALTERATIONS <sup>a</sup> Indeterminate  Absent  Present, describe
Present, describe  TESTING METHOD (select all that apply)  ISH  NGS  Other, specify	TESTING METHOD <sup>b</sup> (select all that apply)  IHC  ISH  NGS  Other, specify
TERT PROMOTER ALTERATIONS <sup>a</sup> Indeterminate Absent Hotspot variant (C228T or C250T) Other sequence variant, specify	YAP1 REARRANGEMENT <sup>a</sup> Indeterminate Absent Present, describe
TESTING METHOD (select all that apply)  Sanger sequencing NGS PCR-based method Other, specify	TESTING METHOD (select all that apply)  ISH  NGS  Other, specify
TP53 ALTERATIONS <sup>a</sup> TP53 variant Indeterminate Absent Present, describe	ZFTA REARRANGEMENT <sup>a</sup> Indeterminate Absent Present, describe  TESTING METHOD (select all that apply)  IHC
EXONS ANALYSED  Exons 5-8  All exons  Other, specify	ISH NGS Other, specify  L1CAM expression (IHC)
TESTING METHOD (select all that apply)  Sanger sequencing NGS PCR-based method IHC	☐ Indeterminate ☐ Negative ☐ Positive  RELA rearrangement ☐ Indeterminate ☐ Absent ☐ Present, describe
p53 expression  Negative or rare, lightly positive cells  Intermediate (intermediate numbers of predominantly lightly positive cells)  Positive (diffuse and strong nuclear positivity)  Other, specify	TESTING METHOD (select all that apply)  ISH  NGS  Other, specify
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.	<sup>b</sup> Repeat for each alteration.

,	, ,
OTHER IMMUNOHISTOCHEMISTRY FINDINGS <sup>a</sup>	
None identified	
=	
Present, record test(s), methodology and results	
*	
a	
<sup>a</sup> Only core for some tumours - refer to Tables 1-3.	
OTHER MOLECULAR FINDINGS	
None identified	
Present, record test(s), methodology and results	
▼ [	